As part of the EU response to the coronavirus pandemic, the Innovative Medicines Initiative is mobilising €117 million in public and private funding to 8 research projects selected from nearly 150 proposals.

The selected research projects will cover 2 vital categories of research: diagnostics and treatments.

- **Total funding amount:** €117 million
- **IMI contribution:** €72 million
- **Contribution from EFPIA, IMI Associated Partners & other organisations:** €45 million
- **More than 40 universities and public research bodies**
- **40 private companies**, including 21 SMEs
- **Over 90 partners selected from 18 countries**

- **Number of projects selected for funding:** 8
- **Project partners include philanthropic foundations and charities**

For more information, visit imi.europa.eu or follow @imi_ju #IMICarryTheTorch
What research will be funded?

**TREATMENTS:** selected projects

**CARE** will explore whether existing drugs could be effective as treatments for COVID-19, and develop new drugs specially designed to tackle the SARS-CoV-2 virus. With 36 partners, the aim is to launch clinical trials of the most promising drug candidates.

**IMPENTRI** will run a randomised, double-blind clinical trial to properly test the efficacy of the generic drug imatinib as a treatment for COVID-19 patients with severe lung inflammation.

**MAD-COV 2** will study the molecular details of the SARS-CoV-2 virus and use their findings to develop new COVID-19 treatments.

**WHAT ELSE IS IMI DOING?**

Since 2008, IMI has funded 150 research projects, some of which are currently contributing to the effort to find solutions to the coronavirus pandemic. While some of the projects are working on infectious and zoonotic diseases, others are concerned with data management and antimicrobial resistance. They are sharing their tools, expertise, and networks created as part of IMI-funded research to contribute to the wider EU response. Find out more on our website.

**DIAGNOSTICS:** selected projects

**COVID-RED** will combine expertise in clinical epidemiology with digital devices like wearables and mobile apps to rapidly and reliably detect cases so that they can be prioritised for testing.

**DECISION** will work on a low-cost, high-quality, miniaturised, disposable molecular diagnostic system that will make it possible to test patients with laboratory quality performance pretty much anywhere and give them their results in minutes.

**DRAGON** will apply artificial intelligence and machine learning to create a decision support system for better and more rapid diagnosis and prognosis. Citizens and patients will be involved in the development of the system.

**KRONO** aims to deliver a simple test that can be used in a doctor’s surgery (or even at a patient’s home) and would deliver results in just 40 minutes.

**RAPID-COVID** aims to develop a diagnostic test that can simultaneously detect SARS-CoV-2 as well as 30 other common respiratory bacteria and viruses, to ensure COVID-19 patients are isolated quickly and that all patients receive the right treatment, avoiding unnecessary use of antibiotics.

For more information, visit imi.europa.eu or follow @imi_ju #IMICarryTheTorch

EU efpià